slc25a35 Antibody

What is SLC25A35 and why is it important in scientific research?

SLC25A35 is a member of the solute carrier family 25 (SLC25), which consists of mitochondrial carrier proteins that transport molecules across the mitochondrial inner membrane. This protein has been identified as a crucial regulator of mitochondrial metabolism, particularly in enhancing fatty acid oxidation (FAO) and mitochondrial biogenesis . Recent research has revealed that SLC25A35 markedly reprograms mitochondrial metabolism, characterized by increased oxygen consumption rate and ATP production while decreasing reactive oxygen species (ROS) levels . The protein has gained significant research interest due to its potential role in cancer development, particularly in hepatocellular carcinoma (HCC), where it appears to have oncogenic properties by promoting proliferation and metastasis . Additionally, altered expression of SLC25 family genes, including SLC25A35, may serve as markers of mitochondrial dysfunction in various pathological conditions.

What types of SLC25A35 antibodies are available for research applications?

Several types of SLC25A35 antibodies are available for research, with variations in host species, target regions, and conjugation status. Polyclonal antibodies against different regions of the SLC25A35 protein are commonly used, including those targeting the N-terminal, middle region, and specific amino acid sequences (such as AA 120-168) . The most widely documented in the literature is the rabbit polyclonal antibody targeting the middle region of SLC25A35, which has been validated for Western blotting applications . Additionally, conjugated antibodies including FITC, biotin, and HRP-labeled variants are available for specific detection methods such as immunohistochemistry, ELISA, and flow cytometry . When selecting an antibody, researchers should consider the specific application requirements, species reactivity needs, and whether a conjugated or unconjugated format would be most suitable for their experimental design.

How can SLC25A35 antibodies be used to study mitochondrial metabolism in cancer research?

SLC25A35 antibodies provide valuable tools for investigating the protein's role in reprogramming mitochondrial metabolism in cancer cells. Researchers can utilize these antibodies in Western blotting to quantify SLC25A35 expression levels in different cancer cell lines or tumor samples, correlating expression with metabolic phenotypes . Immunoprecipitation with SLC25A35 antibodies can help identify interaction partners that might mediate its effects on metabolism. For investigating subcellular localization, immunofluorescence staining using SLC25A35 antibodies can confirm mitochondrial targeting and potential redistribution under various conditions. Recent research has demonstrated that SLC25A35 enhances mitochondrial oxidative respiration and ATP production while decreasing oxidative stress in hepatocellular carcinoma cells, suggesting its critical role in cancer cell metabolism . These findings can be further explored using SLC25A35 antibodies in conjunction with metabolic assays such as Seahorse analysis to establish mechanistic connections between protein expression and cellular metabolic reprogramming.

What are the best experimental approaches to study SLC25A35's role in fatty acid oxidation using specific antibodies?

To investigate SLC25A35's role in fatty acid oxidation, researchers should implement a multi-faceted experimental approach combining antibody-based detection with metabolic assays. First, establish baseline SLC25A35 expression using Western blotting with validated antibodies in the cell types of interest, followed by gene silencing (siRNA/shRNA) or overexpression experiments to manipulate SLC25A35 levels . Functional assessment of fatty acid oxidation can be performed using radiolabeled fatty acid substrates or Seahorse XF analyzers to measure oxygen consumption rates (OCR) in response to fatty acid addition, correlating these measurements with SLC25A35 expression levels . Co-immunoprecipitation experiments using SLC25A35 antibodies can identify protein interactions with known FAO regulatory proteins. Recent research has revealed that SLC25A35 facilitates FAO through upregulating peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) via increased acetyl-CoA-mediated acetylation . Researchers can verify this mechanism by assessing PGC-1α acetylation status and acetyl-CoA levels in conjunction with SLC25A35 expression manipulation.

How can researchers effectively use SLC25A35 antibodies to analyze protein interactions in mitochondrial biogenesis pathways?

Analyzing SLC25A35's role in protein interactions within mitochondrial biogenesis pathways requires strategic application of antibody-based techniques. Co-immunoprecipitation using SLC25A35 antibodies followed by mass spectrometry represents a powerful approach to identify novel interaction partners in an unbiased manner . For validation of specific interactions, such as with PGC-1α, researchers should perform reciprocal co-immunoprecipitation experiments using antibodies against both proteins. Proximity ligation assays can provide spatial information about protein interactions within intact cells, offering insights into the subcellular compartments where these interactions occur. Chromatin immunoprecipitation (ChIP) using antibodies against transcription factors regulated by SLC25A35 (such as PGC-1α) can identify genomic targets affected by SLC25A35-mediated signaling . Recent research has established that SLC25A35 enhances mitochondrial biogenesis characterized by increased mitochondrial mass and DNA content, which researchers can correlate with protein interaction data to construct comprehensive signaling pathways .

What are the critical considerations for optimizing Western blot protocols with SLC25A35 antibodies?

Successful Western blot analysis of SLC25A35 requires careful optimization of several parameters to ensure specific detection of this mitochondrial carrier protein. Sample preparation is crucial—researchers should use mitochondrial fractionation techniques to enrich for SLC25A35, as whole cell lysates may yield weaker signals due to the protein's localization . The antibody selection should prioritize those validated specifically for Western blotting applications, such as the rabbit polyclonal antibody against the middle region of SLC25A35 (ABIN5517415) . Optimization of antibody concentration is essential, with initial testing recommended at 1:500-1:2000 dilutions followed by adjustment based on signal-to-noise ratio. Blocking conditions should be carefully optimized, with 5% non-fat dry milk or BSA in TBST typically providing good results for polyclonal antibodies. For detection of post-translational modifications, such as acetylation states that might affect SLC25A35 function, specialized lysis buffers containing deacetylase inhibitors should be employed to preserve these modifications .

How should researchers design knockdown and overexpression experiments to study SLC25A35 function?

Designing effective knockdown and overexpression experiments for SLC25A35 functional studies requires careful consideration of several methodological aspects. For knockdown approaches, researchers should design at least two distinct siRNAs or shRNAs targeting different regions of SLC25A35 mRNA to control for off-target effects, similar to the approach used in recent studies where two distinct siRNAs were employed to silence SLC25A35 in SNU-739 and SNU-354 cells . Stable knockdown using lentiviral-delivered shRNAs is recommended for long-term experiments such as xenograft models, as demonstrated in the subcutaneous xenograft mice model using stable SLC25A35 knockdown SNU-739 cells . For overexpression studies, researchers should consider using expression vectors with epitope tags that do not interfere with mitochondrial targeting sequences to allow tracking of the exogenous protein. Validation of knockdown or overexpression efficiency is critical and should be performed using both qRT-PCR and Western blotting with well-characterized SLC25A35 antibodies . Rescue experiments, where wild-type SLC25A35 is reintroduced into knockdown cells, provide strong evidence for phenotype specificity.

What controls should be included when using SLC25A35 antibodies for immunohistochemistry in tissue samples?

Rigorous controls are essential when performing immunohistochemistry (IHC) with SLC25A35 antibodies to ensure reliable and interpretable results. Positive controls should include tissues known to express SLC25A35, such as liver tissues that show high SLC25A35 expression based on previous studies . Negative controls should include tissues from SLC25A35 knockout models when available or samples where the primary antibody is omitted but all other steps are identical. Isotype controls using non-specific IgG from the same host species as the SLC25A35 antibody at equivalent concentrations help identify non-specific binding . Peptide competition assays, where the antibody is pre-incubated with the immunizing peptide before application to tissue, provide further validation of specificity. Recent research utilized IHC staining to confirm decreased expression of SLC25A35 in xenograft tumors derived from SLC25A35-knockdown cells compared to control tumors, demonstrating the utility of this approach for validating in vivo manipulations of SLC25A35 expression . When analyzing human samples, researchers should include multiple cases representing different expression levels to establish a reliable scoring system.

How should researchers interpret differences in SLC25A35 expression patterns between normal and diseased tissues?

Interpreting SLC25A35 expression differences between normal and diseased tissues requires thorough analysis and consideration of several factors. Researchers should first establish baseline expression levels in normal tissues across different cell types, as mitochondrial proteins may show cell-type-specific expression patterns. When analyzing diseased tissues, such as hepatocellular carcinoma samples where SLC25A35 has been found to be highly expressed, researchers should correlate expression levels with clinical parameters and patient outcomes . Recent research demonstrated that high SLC25A35 expression in HCC correlated with adverse patient survival, suggesting its potential value as a prognostic marker . Expression patterns should be analyzed both at the protein level using validated antibodies and at the mRNA level using techniques such as qRT-PCR or RNA-seq to distinguish transcriptional from post-transcriptional regulation. Researchers should consider the heterogeneity within tissue samples, potentially utilizing techniques such as laser capture microdissection to isolate specific cell populations before expression analysis.

What are common issues when detecting SLC25A35 in different cellular compartments and how can they be resolved?

Detecting SLC25A35 across different cellular compartments presents several challenges that require specific troubleshooting approaches. As a mitochondrial carrier protein, SLC25A35 is primarily localized to mitochondria, but conventional cell fractionation protocols may yield inconsistent results due to mitochondrial fragmentation during isolation procedures. Researchers can improve detection by using gentler mitochondrial isolation methods that preserve membrane integrity, such as nitrogen cavitation or differential centrifugation with protease inhibitors . For immunofluorescence detection, mitochondrial membrane potential-dependent probes (like MitoTracker) should be used as co-localization markers before fixation to confirm mitochondrial staining patterns. Non-specific background staining can be reduced by careful optimization of antibody concentrations and incubation conditions, with signal amplification systems like tyramide signal amplification being useful for detecting low abundance targets. When studying potential shuttling between compartments, researchers should consider live-cell imaging with fluorescently-tagged SLC25A35 constructs to complement fixed-cell antibody staining approaches.

How can researchers reconcile contradictory findings when studying SLC25A35 function across different experimental models?

Reconciling contradictory findings about SLC25A35 function across experimental models requires systematic evaluation of methodological differences and biological context. Researchers should first examine differences in cellular models, as recent studies show variable SLC25A35 expression across HCC cell lines, which may reflect diverse roles in different cellular contexts . The methods used for manipulating SLC25A35 expression (transient versus stable, partial versus complete knockdown) should be compared, as these can yield different phenotypic outcomes. Temporal aspects are crucial—acute versus chronic SLC25A35 depletion may trigger different compensatory mechanisms involving other SLC25 family members, as suggested by studies showing altered expression of multiple SLC25 genes in pathological conditions . Differences in experimental readouts must be considered; for example, contradictory findings regarding ROS levels might result from different detection methods or cellular states. When contradictions arise between in vitro and in vivo findings, researchers should consider the tumor microenvironment's influence, as recent analyses indicate SLC25A35 expression correlates with immune cell infiltration in HCC .

What are the future directions for SLC25A35 antibody applications in research?

The future of SLC25A35 antibody applications in research holds significant promise for advancing our understanding of mitochondrial metabolism in health and disease. Development of highly specific monoclonal antibodies against different domains and post-translationally modified forms of SLC25A35 will enable more precise characterization of this protein's regulation and function. Application of advanced imaging techniques such as super-resolution microscopy using SLC25A35 antibodies will reveal detailed subcellular localization and potential dynamic changes in response to metabolic perturbations. Implementation of proximity-dependent biotinylation approaches combined with SLC25A35 antibodies will map the protein's interaction network in different cellular contexts and disease states. Recent research highlighting SLC25A35's role in promoting fatty acid oxidation and mitochondrial biogenesis through PGC-1α regulation opens avenues for investigating therapeutic targeting strategies in cancers where SLC25A35 is overexpressed . Development of antibodies suitable for therapeutic applications, such as antibody-drug conjugates targeting cancer cells with high SLC25A35 expression, represents a promising translational direction.